Conformational and molecular basis for induction of apoptosis by a p53 C-terminal peptide in human cancer cells

被引:107
作者
Kim, AL
Raffo, AJ
Brandt-Rauf, PW
Pincus, MR
Monaco, R
Abarzua, P
Fine, RL
机构
[1] Columbia Univ Coll Phys & Surg, Expt Therapeut Program, Div Med Oncol, New York, NY 10032 USA
[2] Vet Adm Med Ctr, Dept Pathol & Lab Med, Brooklyn, NY 11209 USA
[3] SUNY Hlth Sci Ctr, Brooklyn, NY 11203 USA
[4] Columbia Univ, Sch Publ Hlth, New York, NY 10032 USA
[5] Hoffmann La Roche Inc, Nutley, NJ 07110 USA
关键词
D O I
10.1074/jbc.274.49.34924
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
A p53-derived C-terminal peptide induced rapid apoptosis in breast cancer cell lines carrying endogenous p53 mutations or overexpressed wild-type (wt) p53 but was not toxic to nonmalignant human cell lines containing wt p53, Apoptosis occurred through a Fas/APO-1 signaling pathway involving increased extracellular levels of Fas/FasL in the absence of protein synthesis, as well as activation of a Fas/APO-1-specific protease, FLICE, The peptide activity was p53-dependent, and it had no effect in three tumor cell lines with null p53. Furthermore, the C-terminal peptide bound to p53 protein in cell extracts. Thus, p53-dependent, Fas/APO-1 mediated apoptosis can be induced in breast cancer cells with mutant p53 similar to the recently described Fas/APO-1 induced apoptosis by wt p53. However, mutant p53 without p53 peptide does not induce a Fas/APO-1 activation or apoptosis, Docking of the computed low energy conformations for the C-terminal peptide with those for a recently defined proline-rich regulatory region from the N-terminal domain of p53 suggests a unique low energy complex between the two peptide domains. The selective and rapid induction of apoptosis in cancer cells carrying p53 abnormalities may lead to a novel therapeutic modality.
引用
收藏
页码:34924 / 34931
页数:8
相关论文
共 47 条
[31]  
PINCUS MR, 1988, INT J QUANTUM CHEM Q, V15, P209
[32]   Somatic frameshift mutations in the BAX gene in colon cancers of the microsatellite mutator phenotype [J].
Rampino, N ;
Yamamoto, H ;
Ionov, Y ;
Li, Y ;
Sawai, H ;
Reed, JC ;
Perucho, M .
SCIENCE, 1997, 275 (5302) :967-969
[33]   Double identity for proteins of the Bcl-2 family [J].
Reed, JC .
NATURE, 1997, 387 (6635) :773-776
[34]   Caspases: Intracellular signaling by proteolysis [J].
Salvesen, GS ;
Dixit, VM .
CELL, 1997, 91 (04) :443-446
[35]  
Selivanova G, 1999, MOL CELL BIOL, V19, P3395
[36]   Restoration of the growth suppression function of mutant p53 by a synthetic peptide derived from the p53 C-terminal domain [J].
Selivanova, G ;
Iotsova, V ;
Okan, I ;
Fritsche, M ;
Strom, M ;
Groner, B ;
Grafstrom, RC ;
Wiman, KG .
NATURE MEDICINE, 1997, 3 (06) :632-638
[37]  
SHAH D, 1989, INT J PEPT PROT RES, V34, P325
[38]  
SOUSSI T, 1990, ONCOGENE, V5, P945
[39]   Induction of CPP32-like activity in PC12 cells by withdrawal of trophic support - Dissociation from apoptosis [J].
Stefanis, L ;
Park, DS ;
Yan, CYI ;
Farinelli, SE ;
Troy, CM ;
Shelanski, ML ;
Greene, LA .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1996, 271 (48) :30663-30671
[40]   ACCUMULATION OF P53 TUMOR SUPPRESSOR GENE PROTEIN - AN INDEPENDENT MARKER OF PROGNOSIS IN BREAST CANCERS [J].
THOR, AD ;
MOORE, DH ;
EDGERTON, SM ;
KAWASAKI, ES ;
REIHSAUS, E ;
LYNCH, HT ;
MARCUS, JN ;
SCHWARTZ, L ;
CHEN, LC ;
MAYALL, BH ;
SMITH, HS .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1992, 84 (11) :845-855